Scribe Therapeutics is a biotechnology company specializing in molecular engineering to develop advanced in vivo therapies that target the root causes of diseases. Founded by pioneers of CRISPR technology, Scribe aims to enhance genome editing capabilities through its proprietary CRISPR by Design™ platform, which incorporates custom-engineered enzymes and innovative delivery methods. The company is committed to addressing limitations in current CRISPR technologies and is focused on advancing the field of genetic medicine. Scribe Therapeutics fosters a collaborative and dynamic work environment, where creativity and interdisciplinary cooperation are encouraged to facilitate the development of next-generation therapeutics. Through its cutting-edge research and commitment to quality, Scribe is dedicated to making impactful contributions to healthcare and improving patient outcomes.